Sunday - July 6, 2025
IMAAVYShowed Greater Sustained Disease Control Versus Approved FcRn Blockers for Generalized Myasthenia Gravis at Multiple Timepoints Over 24 Weeks in Newly Published Indirect Treatment Comparison
June 25, 2025
RARITAN, New Jersey, June 25 -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release:

* * *

IMAAVYTM (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)

The ITC compared all published Phase 3 data of . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products